Skip to content
Biodatica
Start free

XBiotech, Inc.

Tucson, Arizona

OncologyPhase IIListed · XBIT

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

NIH R01 · $0.7M · Therapeutic Modulation of Atrial Remodeling

May 2025Grant renewalMay 30, 2025Source filing (opens the source filing in a new tab)

Momentum

45no change

Momentum 45 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Grant

    R01 · $514k · non-dilutive

    Jun 1, 2025

    MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI PARK, DONGKEUN · NIBIB · award ends May 31, 2029 · A Portable, Liquid-Helium-Free 1-T/560-mm RT bore Point-of-Care MRI Magnet: Prototype Demonstration

    NIH RePORTER · NIH RePORTER 11029702 (opens the source filing in a new tab)

  2. Grant

    U54 · $419k · non-dilutive

    Feb 1, 2025

    BROAD INSTITUTE, INC. · PI PARK, DANIEL JOHN · NIA · award ends Jan 31, 2030 · Data Analysis and Submission Core: Enabling rapid analysis and public sharing of human virome data

    NIH RePORTER · NIH RePORTER 10990197 (opens the source filing in a new tab)

  3. Grant

    R01 · $696k · non-dilutive

    Jul 1, 2024

    NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PARK, DAVID S · NHLBI · award ends May 31, 2028 · Therapeutic Modulation of Atrial Remodeling

    NIH RePORTER · NIH RePORTER 11117155 (opens the source filing in a new tab)

  4. Trial

    PHASE1/PHASE2 registered

    May 27, 2021

    Pancreatic Cancer · ACTIVE_NOT_RECRUITING · sponsor: XBiotech, Inc. · XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

    ClinicalTrials.gov · NCT04825288 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources